GSK beat six other companies to the Sierra deal table and prevailed after initial $46 per share bid

Within weeks of Sierra Oncology revealing it had taken a failed Gilead JAK inhibitor and turned it into a Phase III success, GlaxoSmithKline quickly swooped in and wanted a piece of the potential earnings, should the drug, momelotinib, receive an FDA nod. At first, the idea was a strategic partnership.…

...

Click to view original post